Price
No data yet.
Social Signal Score
Revenue
$0.00-100.00%Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Daniel Tassé
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 161
- Beta
- -0.21
- Country
- FR
- Piotroski score
- 2 / 9 (Weak)
- Altman Z-score
- -0.45
Financials
Revenue
$0.00-100.0%Net Income
$-50.40MEBITDA
$-51.30MFree Cash Flow
$-83.07MEPS (diluted)
$-0.49Shares Outstanding (diluted)
85.66M+248.9%Operating Expenses
$51.30MCash & Debt
$174.90MReturn of Capital
$0.00Quote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $0.00 | $-146.95M | $-1.70 |
| 2024 | $0.00 | $-113.72M | $-1.20 |
| 2023 | $15.73M | $-72.73M | $-0.75 |
| 2022 | $4.84M | $-96.27M | $-1.25 |
| 2021 | $5.71M | $-97.81M | $-1.80 |
| 2020 | $11.28M | $-159.56M | $-2.95 |
| 2019 | $14.71M | $-172.01M | $-2.90 |
| 2018 | $12.81M | $-190.26M | $-3.05 |
| 2017 | $11.52M | $-177.20M | $-5.95 |
| 2016 | $7.93M | $-126.35M | $-4.70 |
| 2015 | $220.8K | $-48.52M | $-2.10 |
| 2014 | $256.6K | $-29.07M | $-1.75 |
| 2013 | $251.3K | $-26.59M | $-1.95 |
| 2012 | $230.6K | $-17.02M | $-1.30 |
Valuation
DBVThas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
100+0.00%Social Signal Score
Mentions (2)
- Newsglobenewswire.com·1d ago·Neutral
…tember 3, 2026 DBV Technologies to Participate in Upcoming September Investor Conferences DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT) (the “Company”), a late-stage biopharmaceutical company, today announced the company will participate at the following investor conferences in September: 2026 Cantor Global Healthcare Conference – September 9, 2026 Format: Fireside Chat Time: 1:00pm ETLocation: New York, NY Citi's 2026 Biopharma Back t…
View source ↗ - Newsglobenewswire.com·2d ago·Neutral
Information Regarding the Total Number of Voting Rights and Total Number of Shares of the Company as of August 31, 2026 Information Regarding the Total Number of Voting Rights and Total Number of Shares of the Company as of August 31, 2026
View source ↗
Earnings
Wed, Oct 28(in 8 weeks)
Consensus estimate $-0.16 per share
Typical surprise -8.3% (median, so one quarter with a near-zero estimate can't distort it)
- Thu, Jul 16$-0.14 vs $-0.12miss
- Thu, Apr 30$-0.56 vs $-0.14miss
- Fri, Mar 27$-1.15 vs $-1.30beat
- Tue, Oct 28$-0.34 vs $-1.45beat
- Wed, Jul 30$-1.55 vs $-0.21miss
- Wed, Apr 30$-0.26 vs $-0.24miss
Estimates and results for DBVT via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by DBVT officers and directors.
- Bought
- $571k
- Sold
- $15.5m
10 trades
19 trades
- Mohideen Pharissold
- Mohideen Pharissold
- Epic Bpifrancesold
- Epic Bpifrancesold
- Epic Bpifrancesold
- Mohideen Pharissold
- Mohideen Pharissold
- Mohideen Pharissold
71 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.